Permanent scars affect many millions of people each year and are an avoidable consequence of skin trauma. Scars are areas of fibrous tissue that result from the physiological process of wound repair. This scar tissue is of inferior quality to the tissue that it replaces, both mechanically and functionally. For example, scars typically have, at best, 70% - 80% of the tensile strength of normal skin.

The severity of scarring in patients is generally related to the degree of wound trauma, with the degree of disfigurement depending on their location on the body and their severity. However, scarring is particularly excessive and disfiguring in around one third of cases (classified as pathological scarring).

Scarring in the skin is an inevitable outcome following surgery or trauma and is the cause of significant distress for both patients and their loved-ones, through its effect on a person's appearance, function and self-worth.

There are currently no reliably effective marketed treatments to reduce or prevent scarring.

As such, scarring represents a significant area of unmet medical need. With the increasing emphasis on aesthetic appearance, there is also a high consumer demand for scar preventing and reducing pharmaceuticals.


PharmEcosse has acquired the license rights to a clinical-stage program in scar prevention. Arising from extensive research conducted by the company's scientific founder the program will be progressed by the company to establish clinical efficacy.

Photo of a man's chest with severe post-operative scarring